• Basic Info
• Top Questions
• Clinical Info
• Interactions

Uses

Acute Otitis Media (AOM)

Treatment of AOM caused by S. pneumoniae, H. influenzae (including β-lactamase-producing strains), or M. catarrhalis (including β-lactamase-producing strains).

Pharyngitis and Tonsillitis

Treatment of pharyngitis and tonsillitis caused by S. pyogenes (group A β-hemolytic streptococci). Generally effective in eradicating S. pyogenes from the nasopharynx, but efficacy in prevention of subsequent rheumatic fever has not been established to date.

CDC, AAP, IDSA, AHA, and others recommend oral penicillin V or IM penicillin G benzathine as treatments of choice; oral cephalosporins and oral macrolides considered alternatives. Amoxicillin sometimes used instead of penicillin V, especially for young children.

Respiratory Tract Infections

Treatment of acute sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), or Moraxella catarrhalis (including β-lactamase-producing strains).

Treatment of secondary bacterial infections of acute bronchitis caused by susceptible S. pneumoniae, H. influenzae (including β-lactamase-producing strains), or M. catarrhalis (including β-lactamase-producing strains).

Treatment of acute bacterial exacerbation of chronic bronchitis caused by susceptible S. pneumoniae, H. influenzae (including β-lactamase producing strains), or M. catarrhalis (including β-lactamase producing strains).

Treatment of mild to moderate community-acquired pneumonia† (CAP).

Skin and Skin Structure Infections

Treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or S. pyogenes.

Also has been used for treatment of uncomplicated skin and skin structure infections caused by S. epidermidis†, S. saprophyticus†, group B or G streptococci†, E. coli†, or K. pneumoniae†.

Dosage and Administration

Administration

Oral Administration

Administer orally without regard to meals.

Dosage

Available as cefprozil monohydrate; dosage expressed as anhydrous cefprozil.

Pediatric Patients

Acute Otitis Media (AOM)

Oral

Children 6 months to 12 years of age: 15 mg/kg every 12 hours for 10 days.

Pharyngitis or Tonsillitis

Oral

Children 2–12 years of age: 7.5 mg/kg every 12 hours for 10 days.

Children ≥13 years of age: 500 mg once daily for 10 days.

Respiratory Tract Infections

Acute Sinusitis

Oral

Children 6 months to 12 years of age: 7.5 mg/kg every 12 hours for 10 days. For moderate to severe infections, 15 mg/kg every 12 hours for 10 days.

Children ≥13 years of age: 250 mg every 12 hours for 10 days. For moderate to severe infections, 500 mg every 12 hours for 10 days.

Secondary Bacterial Infections of Acute Bronchitis

Oral

Children ≥13 years of age: 500 mg every 12 hours for 10 days.

Acute Exacerbations of Chronic Bronchitis

Oral

Children ≥13 years of age: 500 mg every 12 hours for 10 days.

Skin and Skin Structure Infections

Oral

Children 2–12 years of age: 20 mg/kg once every 24 hours for 10 days.

Children ≥13 years of age: 250 or 500 mg every 12 hours for 10 days or 500 mg once daily for 10 days.

Adults

Pharyngitis or Tonsillitis

Oral

500 mg once daily for 10 days.

Respiratory Tract Infections

Acute Sinusitis

Oral

250 mg every 12 hours for 10 days. For moderate to severe infections, 500 mg every 12 hours for 10 days.

Secondary Bacterial Infections of Acute Bronchitis

Oral

500 mg every 12 hours for 10 days.

Acute Exacerbations of Chronic Bronchitis

Oral

500 mg every 12 hours for 10 days.

Skin and Skin Structure Infections

Oral

250 or 500 mg every 12 hours for 10 days or 500 mg once daily for 10 days.

Special Populations

Dosage in Hepatic Impairment

No dosage adjustments required.

Dosage in Renal Impairment

No dosage adjustments required in patients with Cl_cr ≥30 mL/minute.

Patients with Cl_cr <30 mL/minute: administer 50% of the usual dose using the usual dosing intervals.

Hemodialysis patients: administer cefprozil doses after dialysis sessions.

Geriatric Patients

No dosage adjustments required except those related to renal impairment. Cautious dosage selection because of age-related decreases in renal function. See Renal Impairment under Dosage and Administration.